ECoG BMI for Motor and Speech Control (BRAVO)
A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Adelyn Tu-Chan
- Phone Number: (415) 575-0431
- Email: adelyn.tu@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- Recruiting
- University of California San Francisco
-
Contact:
- Adelyn Tu-Chan
- Phone Number: (415) 575-0431
- Email: adelyn.tu@ucsf.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 21
- Limited ability to use upper limbs, based on neurological examination, due to stroke, amyotrophic lateral sclerosis (ALS), multiple sclerosis, cervical spinal cord injury, brainstem stroke, muscular dystrophy, myopathy or severe neuropathy.
- Disability, defined by a 4 or greater score on the Modified Rankin Scale, must be severe enough to cause loss of independence and inability to perform activities of daily living.
- If stroke or spinal cord injury, at least 1 year has passed since onset of symptoms
- Must live within a two-hour drive of UCSF
Exclusion Criteria:
- Pregnancy or breastfeeding
- Inability to understand and/or read English
- Inability to give consent
- Dementia, based on history, physical exam, and MMSE
- Active depression (BDI > 20) or other psychiatric illness (active general anxiety disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD), or personality disorders (e.g. multiple personality disorder, borderline personality disorder, etc.)
- History of suicide attempt or suicidal ideation
- History of substance abuse
- Co-morbidities including ongoing anticoagulation, uncontrolled hypertension, cancer, or major organ system failure
- Inability to comply with study follow-up visits
- Any prior intracranial surgery
- History of seizures
- Immunocompromised
- Has an active infection
- Has a CSF drainage system or an active CSF leak
- Requires diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) to treat a chronic condition
- Has an implanted electronic device such as a neurostimulator, cardiac pacemaker/defibrillator or medication pump, or presence of any head or neck metallic foreign bodies
- Allergies or known hypersensitivity to materials in the Blackrock NeuroPort Array (i.e. silicone, titanium) or the PMT Subdural Cortical Electrode (silicone, platinum iridium, nichrome)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Electrocorticography-based brain computer interface
|
PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Up to 6 years post-implant period
|
The primary endpoint of this study is to determine the incidence of treatment-emergent adverse events associated with the ECoG-based interface
|
Up to 6 years post-implant period
|
|
NIDCD Primary Objective 1
Time Frame: Up to 6 years post-implant period
|
To enable communication via text decoded from neural signals.
|
Up to 6 years post-implant period
|
|
NIDCD Primary Objective 2
Time Frame: Up to 6 years post-implant period
|
To enable communication via synthesized speech decoded from neural signals.
|
Up to 6 years post-implant period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NIDCD Secondary Objective 1
Time Frame: Up to 6 years post-implant period
|
To evaluate communication via text decoded from neural signals.
|
Up to 6 years post-implant period
|
|
NIDCD Secondary Objective 2
Time Frame: Up to 6 years post-implant period
|
To evaluate communication via synthesized speech decoded from neural signals.
|
Up to 6 years post-implant period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Karunesh Ganguly, MD, PhD, University of California, San Francisco
Publications and helpful links
General Publications
- Metzger SL, Liu JR, Moses DA, Dougherty ME, Seaton MP, Littlejohn KT, Chartier J, Anumanchipalli GK, Tu-Chan A, Ganguly K, Chang EF. Generalizable spelling using a speech neuroprosthesis in an individual with severe limb and vocal paralysis. Nat Commun. 2022 Nov 8;13(1):6510. doi: 10.1038/s41467-022-33611-3.
- Moses DA, Metzger SL, Liu JR, Anumanchipalli GK, Makin JG, Sun PF, Chartier J, Dougherty ME, Liu PM, Abrams GM, Tu-Chan A, Ganguly K, Chang EF. Neuroprosthesis for Decoding Speech in a Paralyzed Person with Anarthria. N Engl J Med. 2021 Jul 15;385(3):217-227. doi: 10.1056/NEJMoa2027540.
- Silva AB, Liu JR, Anderson VR, Kurtz-Miott CM, Hallinan IP, Littlejohn KT, Brosler SC, Tu-Chan A, Ganguly K, Moses DA, Chang EF. Implications of shared motor and perceptual activations on the sensorimotor cortex for neuroprosthetic decoding. J Neural Eng. 2025 Aug 7;22(4):046039. doi: 10.1088/1741-2552/adf50e.
- Shah AM. Unlocking Naturalistic Speech With Brain-Computer Interface. Artif Organs. 2025 Jul;49(7):1087-1088. doi: 10.1111/aor.15021. Epub 2025 May 12.
- Silva AB, Liu JR, Anderson VR, Kurtz-Miott CM, Hallinan IP, Littlejohn KT, Brosler S, Tu-Chan A, Ganguly K, Moses DA, Chang EF. Implications of shared motor and perceptual activations on the sensorimotor cortex for neuroprosthetic decoding. medRxiv [Preprint]. 2025 Apr 28:2025.04.24.25326368. doi: 10.1101/2025.04.24.25326368.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Muscular Diseases
- Wounds and Injuries
- Neuromuscular Diseases
- Genetic Diseases, Inborn
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Trauma, Nervous System
- Muscular Disorders, Atrophic
- Spinal Cord Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Stroke
- Multiple Sclerosis
- Muscular Dystrophies
- Spinal Cord Injuries
Other Study ID Numbers
Other Study ID Numbers
- 17-23028
- U01DC018671 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.